← Leaderboards
Stefan Roberts
Insoma Bio, Inc.
$3,115,209
Attributed
$3,390,598
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2019–24$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$3,390,598 · 6
By mechanism
R44$1,972,696 · 1
R43$867,124 · 3
R41$550,778 · 2
Top collaborators
- Ashutosh Chilkoti1 shared
- Scott Thomas Hollenbeck1 shared
Most similar at Insoma Bio, Inc.
Same institution · by research overlap
- Scott Thomas Hollenbeck$127,314
Others in their field
Other Emerging Leaders on “Tissues”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Kevin Urdahl · Seattle Children'S Hospital$84,741,409
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$61,115,130
- Leonard Freedman · Leidos Biomedical Research, Inc.$54,559,980
- Sarah Fortune · Harvard School Of Public Health$51,119,645
- Evan Z Macosko · Broad Institute, Inc.$33,867,067
Research focus
TissuesSuccessPropertyPhase TransitionIn VivoScaffoldRepairedOperative Surgical ProceduresProceduresRecombinantsLiquid SubstanceTemperatureVascularizationFormulationRecombinant ProteinsInjectableBody TemperatureCostHistologicSolidProgramsPolymersEvaluationBiomaterial Compatibility
Grant awards (7)
Enhancing Peripheral Nerve Repair with an Injectable Recombinant Polypeptide Scaffold$296,151
R41 · FY2024 · NS · contact PI
An off the shelf alternative to fat transfer for soft tissue repair$293,983
R43 · FY2024 · GM · contact PI
A recombinant matrix to improve autologous tissue grafts$1,035,879
R44 · FY2023 · CA · contact PI
A recombinant elastin skin substitute for the treatment of burns$282,373
R43 · FY2023 · GM · contact PI
A recombinant matrix to improve autologous tissue grafts$936,817
R44 · FY2022 · CA · contact PI
Fully defined matrices for organoid culture$290,768
R43 · FY2021 · DK · contact PI
A recombinant matrix to improve autologous tissue grafts$254,627
R41 · FY2019 · CA · contact PI